Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg): Clinical experience to date

Drugs

Volumn 65, Issue 15, 2005, Pages 2085-2090

  Faye, Ousmane ^a   Roujeau, Jean Claude ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG MEGADOSE; EPIDERMOLYSIS; EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; IMMUNE RESPONSE; MEDICAL LITERATURE; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; STEVENS JOHNSON SYNDROME;

CLINICAL TRIALS; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS; STEVENS-JOHNSON SYNDROME; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 26944496410     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565150-00002     Document Type: Review

References (17)

1. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6
2. Shöpf E, Stühmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-42
3. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85
4. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53
5. Trent JT, Kirsner RS, Romanelli P, et al. Analysis of Intravenous Immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 2003; 139: 39-43
6. Campione E, Marulli GC, Carrozo AM, et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003; 83:430-2
7. Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004; 25 (1): 81-8
8. Trent JT, Kirsner RS, Romanelli P, et al. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004; 140: 890-2
9. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134: 710-4
10. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-15
11. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3
12. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55
13. Stella M, Cassano P, Bolero D, et al. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001; 203: 45-9
14. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32
15. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003; 139: 33-6
16. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 2003; 207: 96-9
17. Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25: 246-55